Ukraine proposes $100 bln US weapons deal for security guarantees - FT
MDxHealth’s shares have tumbled to a 52-week low, touching down at $1.49, representing a sharp 12% decline just in the past week according to InvestingPro data, as the company faces a challenging market environment. With a market capitalization of approximately $76 million, InvestingPro analysis suggests the stock may be undervalued at current levels. This latest price level reflects a significant downturn over the past year, with the MDxHealth ADR experiencing a steep 1-year change, plummeting by nearly 50%. Despite generating revenue growth of 28% in the last twelve months and maintaining a healthy gross profit margin of 61%, the company faces profitability challenges. Investors are closely monitoring the stock, as the diagnostics company grapples with the factors contributing to this decline, including competitive pressures and shifting industry dynamics. The 52-week low serves as a critical indicator for the company’s performance and investor sentiment, marking a period of intense scrutiny and potential reassessment of MDxHealth’s market strategy and growth prospects. Unlock deeper insights into MDXH’s financial health and access exclusive ProTips with InvestingPro’s comprehensive research reports.
In other recent news, MDxHealth reported its fourth-quarter 2024 financial results, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of -$0.14, better than the anticipated -$0.19, and reported revenue of $24.7 million, exceeding the forecasted $22.9 million. This represents a significant year-over-year revenue growth of 28%. The company also noted a gross profit increase of 22% to $15.5 million, although gross margins decreased by 2.6 percentage points to 62.7%. MDxHealth’s operating loss declined by 27% to $4.6 million, and its net loss decreased by 36% to $6.8 million. Additionally, the company’s cash and cash equivalents stood at $46.8 million at the end of 2024. In other developments, MDxHealth CEO Michael McGarrity purchased 50,000 ordinary shares of the company, totaling approximately $80,000. The company has set a revenue guidance of $108-110 million for 2025, targeting a 20% growth, and aims to achieve adjusted EBITDA positivity by the first or second quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.